This trial was conducted to evaluate the safety and effectiveness of using the patient's own blood stem cells in the treatment of end stage liver disease. This study was conducted between July 2005 and November 2012 at the Xijing Hospital in Shanxi province. Four hundred participants with end stage liver disease were allocated into either a treatment group that received an injection of their own stem cells collect from their peripheral blood, or a control group that received conventional treatment only. The participants were monitored for complications and improvements in liver function. The trial is now closed Results do not appear to have been published.